Início
Mercados
Gráficos e ideias
Algo
Notícias
Store
Corretoras
Baixar
Calendário econômico
Sinais de Negociação
Terminal web
Pressione
/
para pesquisar: @user, $symbol, ...
Pesquisar
Login
Criar uma conta
Français
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Italiano
Türkçe
ESLA
#3530
Estrella Immunopharma, Inc. Common Stock
1.2
2
+0.83%
Setor:
Base:
Moeda do lucro:
Faixa diária
Faixa anual
Mudança diária
+0.83%
Mudança mensal
+10.91%
Mudança em 6 meses
+29.79%
Mudança anual
+25.77%
Fechamento anterior
1.2
1
Open
1.2
2
Bid
Ask
Low
1.2
2
High
1.2
2
Volume
1
Mercados
Ações
Cuidados de saúde
ESLA
Open full chart
Financials
Overview
Relatórios
Statistics
Dividends
Quarterly
Annual
Value
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
36.17 M
37.07 M
37.77 M
—
Valuation ratios
Enterprise value
33.13 M
34.28 M
41.83 M
149.91 M
Price to earnings ratio
0.67
0.77
-2.67
-0.42
Price to sales ratio
—
—
—
—
Price to cash flow ratio
-3.55
-9.96
-10.93
-25.78
Price to book ratio
2.17
-13.13
-2.41
-12.16
Enterprise value to EBITDA ratio
—
—
—
—
Profitability ratios
Return on assets %
-0.86
-1.86
-1.36
-4.99
Return on equity %
1.15
0.91
0.49
-1.98
Return on invested capital %
169.42
-275.15
-152.12
361.44
Gross margin %
—
—
—
—
Operating margin %
—
—
—
—
EBITDA margin %
—
—
—
—
Net margin %
—
—
—
—
Liquidity ratios
Quick ratio
—
—
—
—
Current ratio
0.22
0.16
0.15
1.28
Inventory turnover
—
—
—
—
Asset turnover
—
—
—
—
Solvency ratios
Debt to assets ratio
—
—
—
—
Debt to equity ratio
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
Per share metrics
Operating cash flow per share
-0.01
-0.01
-0.02
-0.11
EBIT per share
—
—
—
—
EBITDA per share
—
—
—
—
Total debt per share
—
—
—
—
Cash per share
0.01
0.04
0.04
0.14
Net current asset value per share
0.03
0.04
0.05
0.18
Tangible book value per share
-0.05
-0.17
-0.27
-0.48
Working capital per share
-0.09
-0.21
-0.31
-0.63
Book value per share
-0.05
-0.17
-0.27
-0.48
Notícias
Estrella annonce un taux de réponse complète de 100% dans son essai sur le lymphome
Estrella reports 100% complete response rate in lymphoma trial
Estrella présentera des données de phase 1 sur sa thérapie cellulaire ciblant CD19
Estrella to present phase 1 data on CD19-targeted cell therapy
Estrella Immunopharma reçoit un avis du Nasdaq pour retard de son assemblée annuelle
Estrella Immunopharma receives Nasdaq notice for delayed annual meeting
Estrella Immunopharma clôture une offre directe enregistrée de 8 millions $
Estrella Immunopharma closes $8 million registered direct offering
Le titre de l’action Estrella Immunopharma chute après l’annonce d’une offre de 8 millions $
Estrella Immunopharma stock falls after announcing $8 million offering
Estrella Immunopharma lève 8 millions de dollars via une offre enregistrée
Estrella Immunopharma raises $8 million through registered offering